220 related articles for article (PubMed ID: 32070383)
1. Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC).
Zhu X; Hou R; Li X; Jiang C; Xia W; Fu X
Radiat Oncol; 2020 Feb; 15(1):43. PubMed ID: 32070383
[TBL] [Abstract][Full Text] [Related]
2. Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and dose-volume histogram parameters.
Tang X; Li Y; Tian X; Zhou X; Wang Y; Huang M; Ren L; Zhou L; Xue J; Ding Z; Zhu J; Xu Y; Peng F; Wang J; Lu Y; Gong Y
Radiother Oncol; 2019 Mar; 132():197-203. PubMed ID: 30385172
[TBL] [Abstract][Full Text] [Related]
3. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
[TBL] [Abstract][Full Text] [Related]
4. Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer.
Ito H; Matsuo Y; Ohtsu S; Nishimura T; Terada Y; Sakamoto T; Mizowaki T
Int J Clin Oncol; 2020 Feb; 25(2):274-281. PubMed ID: 31667664
[TBL] [Abstract][Full Text] [Related]
5. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
6. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer.
Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L
Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118
[No Abstract] [Full Text] [Related]
7. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
[TBL] [Abstract][Full Text] [Related]
8. Radiomics Nomogram for Predicting Locoregional Failure in Locally Advanced Non-small Cell Lung Cancer Treated with Definitive Chemoradiotherapy.
Chen X; Tong X; Qiu Q; Sun F; Yin Y; Gong G; Xing L; Sun X
Acad Radiol; 2022 Feb; 29 Suppl 2():S53-S61. PubMed ID: 33308945
[TBL] [Abstract][Full Text] [Related]
9. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
Miura Y; Mouri A; Kaira K; Yamaguchi O; Shiono A; Hashimoto K; Nishihara F; Shinomiya S; Akagami T; Murayama Y; Abe T; Noda SE; Kato S; Kobayashi K; Kagamu H
Thorac Cancer; 2020 May; 11(5):1280-1287. PubMed ID: 32160383
[TBL] [Abstract][Full Text] [Related]
10. Matched-Pair Analysis of High Dose Versus Standard Dose Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Cancer.
Johnson MD; Sura K; Mangona VS; Glick A; Wallace M; Ye H; Grills IS
Clin Lung Cancer; 2017 Mar; 18(2):149-155. PubMed ID: 27426973
[TBL] [Abstract][Full Text] [Related]
11. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
[TBL] [Abstract][Full Text] [Related]
12. Delineating the pattern of treatment for elderly locally advanced NSCLC and predicting outcomes by a validated model: A SEER based analysis.
Guo M; Li B; Yu Y; Wang S; Xu Y; Sun X; Wang L; Yu J
Cancer Med; 2019 May; 8(5):2587-2598. PubMed ID: 30945441
[TBL] [Abstract][Full Text] [Related]
13. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.
Augustyn A; Adams DL; He J; Qiao Y; Verma V; Liao Z; Tang CM; Heymach JV; Tsao AS; Lin SH
Clin Lung Cancer; 2021 May; 22(3):e451-e465. PubMed ID: 32798130
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC.
Guo M; Li W; Li B; Zou B; Wang S; Meng X; Sun X; Yu J; Wang L
Int Immunopharmacol; 2019 Jul; 72():395-401. PubMed ID: 31030095
[TBL] [Abstract][Full Text] [Related]
15. Survival nomogram for patients with initially diagnosed metastatic non-small-cell lung cancer: a SEER-based study.
Wang Y; Pang Z; Chen X; Bie F; Wang Y; Wang G; Liu Q; Du J
Future Oncol; 2019 Oct; 15(29):3395-3409. PubMed ID: 31512954
[No Abstract] [Full Text] [Related]
16. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study.
Zhang Y; Zheng D; Xie J; Li Y; Wang Y; Li C; Xiang J; Zhang Y; Hu H; Sun Y; Chen H
Chest; 2018 Sep; 154(3):501-511. PubMed ID: 29758181
[TBL] [Abstract][Full Text] [Related]
18. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer.
Taugner J; Eze C; Käsmann L; Roengvoraphoj O; Gennen K; Karin M; Petrukhnov O; Tufman A; Belka C; Manapov F
Radiat Oncol; 2020 Jun; 15(1):148. PubMed ID: 32517716
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Amino Y; Kitazono S; Uematsu S; Hasegawa T; Yoshizawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Kasahara K; Nishio M
Int J Clin Oncol; 2020 Jan; 25(1):67-73. PubMed ID: 31506751
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
Sher DJ; Gielda BT; Liptay MJ; Warren WH; Batus M; Fidler MJ; Garg S; Bonomi P
Clin Lung Cancer; 2013 Jul; 14(4):370-5. PubMed ID: 23260389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]